The Eosinophilic esophagitis disease treatment market is projected to grow at a CAGR of 8.43% during the forecast period to reach US$569.591 million by 2027, from US$323.154 million in 2020.
EoE (Eosinophilic esophagitis) is a disease of the chronic type. Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis share symptoms such as chest pain and difficulty swallowing. It was considered a common disease in children for many years but has now grown in cases in young people that can be registered. Common symptoms of EOE are difficulty swallowing, pain in the chest cavity and upper abdomen, and vomiting.
The condition of eosinophilic Esophagitis occurs when the oesophagus is filled with white blood cells, which are also known as eosinophils. These eosinophils should remain inside the digestive tract if they build up elsewhere, creating discomfort and inflammation inside the organ.
The market for eosinophilic esophagitis disease treatment is expected to be pushed by the rising prevalence of type II inflammatory illnesses, such as EoE, advancements in treatment approaches, and fierce competition among competitors for the first FDA-approved medicine to gain a first-mover advantage. EoE has a lot of needs, which is helping the eosinophilic esophagitis medication sector flourish. EoE diagnosis criteria are flawed since they are reliant on professional opinions (agreement among gastroenterologists, allergists, and pathologists) rather than evidence. Because there is no correlation between disease activity and patient symptoms, histologic criteria for EoE are currently unclear, and repeated tissue testing is required to confirm disease initiation.
The following are the symptoms of Eosinophilic Esophagitis in adults and children: In adults, symptoms are the backflow of undigested food, chest pain while chewing food that gets stuck in the esophagus, and difficulty in chewing and swallowing the food. In a child, some symptoms are common, like difficulty swallowing, and food getting stuck in the esophagus, while other symptoms in the child are vomiting, abdominal pain, difficulty eating, and no response to the medication.
The Global Growth Driver
Over the projection period, the worldwide eosinophilic esophagitis market is expected to develop due to increased awareness campaigns for eosinophil-associated illnesses. Various public and medical awareness programs have been designed and implemented to educate the public and medical community about eosinophil-related illnesses, which is expected to fuel market expansion.
The market for eosinophilic esophagitis is being driven by an increase in the occurrences of digestive tract inflammatory illnesses. Eosinophilic esophagitis (EoE) market growth is expected to be boosted by increased allergies in the esophagus, eosinophil build-up, dysphagia, and impaction in the esophagus.
Restraints
The global eosinophilic esophagitis (EoE) market may be hampered by a lack of disease awareness and acceptability of treatment for a given location. For the time being, no specific treatment for eosinophilic esophagitis has been approved. There are numerous hurdles connected with acquiring regulatory permission, which is expected to hamper market expansion over the projection period. Obtaining regulatory approval for the drug is time-consuming and difficult, as regulatory agencies such as the US Food and Drug Administration (FDA) place significant and stringent restrictions on organizations involved in the clinical development, manufacture, marketing, and distribution of drugs.
The World Health Organization has designated COVID-19 as a global health emergency and has an impact on thousands of people around the world. The Eosinophilic esophagitis drug market segments were influenced by the coronavirus sickness, which already impacts these categories. The coronavirus outbreak, being the worst economic shock to date, has seen a rise in the death toll, which is impacting the economies also. Restaurant closures, flight disruptions, travel restrictions, indoor event venues losing permits, customer confidence eroding, stock markets fluctuating, and residents growing frightened are all possible repercussions of chaos.
The COVID-19 outbreak in numerous countries has generated certain challenges in providing Eosinophilic Esophagitis disease therapy, which was provided in hospitals and clinics. The immense demand on hospitals to provide care to COVID-19 patients is one of the issues prohibiting clinics and hospitals from providing therapy for Eosinophilic Esophagitis.
Regional Analysis
With the rising demand for asthma risk-reducing medications and high-end medical treatments, it is predicted that North America will have the biggest market volume in the Eosinophilic Esophagitis Treatment Market.
Because of the increased occurrence of allergies that cause eosinophilic illnesses, Europe is expected to be the second-largest market for eosinophilic esophagitis (EoE). Due to growing awareness and the existence of generic companies, Asia-Pacific is likely to account for the biggest market share in the eosinophilic esophagitis (EoE) market in the forecasted period.
However, in places such as the Middle East, Africa, and South America, high therapeutic costs and a lack of patient information are limiting the eosinophilic esophagitis market.
| Report Metric | Details |
| Market size value in 2020 | US$323.154 million |
| Market size value in 2027 | US$569.591 million |
| Growth Rate | CAGR of 8.43% from 2020 to 2027 |
| Base year | 2020 |
| Forecast period | 2022–2027 |
| Forecast Unit (Value) | USD Million |
| Segments covered | Product Type, Channel, And Geography |
| Regions covered | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies covered | Baker Hughes Incorporated, Halliburton Company, Schlumberger Ltd., E.I. du Pont de Nemours and Company, Pioneer Engineering Services, BASF SE |
| Customization scope | Free report customization with purchase |
Key Market Segments
Frequently Asked Questions (FAQs)
Q1. What is the size of the global eosinophilic esophagitis disease treatment market?
A1. Eosinophilic Esophagitis Disease Treatment Market was valued at US$323.154 million in the year 2020.
Q2. What will be the eosinophilic esophagitis disease treatment market size by 2027?
A2. The eosinophilic esophagitis disease treatment market is projected to reach a market size of US$569.591 million by 2027.
Q3. What are the growth prospects for the eosinophilic esophagitis disease treatment market?
A3. The global eosinophilic esophagitis disease treatment market is projected to grow at a CAGR of 8.43% during the forecast period.
Q4. What factors are anticipated to drive the eosinophilic esophagitis disease treatment market growth?
A4. The global eosinophilic esophagitis market is expected to grow due to increased awareness campaigns for eosinophil-associated illnesses.
Q5. Which region holds the maximum market share in the eosinophilic esophagitis disease treatment market?
A5. North America is expected to hold the largest share in the eosinophilic esophagitis disease treatment market due to the rising demand for asthma risk-reducing medications and high-end medical treatments.
Baker Hughes Incorporated
Halliburton Company
Schlumberger Ltd.
E.I. du Pont de Nemours and Company
Pioneer Engineering Services
BASF SE
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.